Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Operating Expenses: 2009-2024

Historic Operating Expenses for Amicus Therapeutics (FOLD) over the last 16 years, with Dec 2024 value amounting to $450.5 million.

  • Amicus Therapeutics' Operating Expenses rose 8.21% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $504.7 million, marking a year-over-year increase of 14.95%. This contributed to the annual value of $450.5 million for FY2024, which is 2.56% up from last year.
  • Per Amicus Therapeutics' latest filing, its Operating Expenses stood at $450.5 million for FY2024, which was up 2.56% from $439.2 million recorded in FY2023.
  • Over the past 5 years, Amicus Therapeutics' Operating Expenses peaked at $502.8 million during FY2022, and registered a low of $439.2 million during FY2023.
  • In the last 3 years, Amicus Therapeutics' Operating Expenses had a median value of $450.5 million in 2024 and averaged $464.2 million.
  • Per our database at Business Quant, Amicus Therapeutics' Operating Expenses climbed by 5.29% in 2022 and then decreased by 12.63% in 2023.
  • Yearly analysis of 5 years shows Amicus Therapeutics' Operating Expenses stood at $476.8 million in 2020, then increased by 0.13% to $477.5 million in 2021, then increased by 5.29% to $502.8 million in 2022, then fell by 12.63% to $439.2 million in 2023, then grew by 2.56% to $450.5 million in 2024.